Journal of Cardiovascular Pharmacology and Therapeutics

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Save, V.
Right arrow Articles by Rajadhyaksha, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Save, V.
Right arrow Articles by Rajadhyaksha, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 11, No. 4, 262-270 (2006)
DOI: 10.1177/1074248406295523

Effect of Atorvastatin on Type 2 Diabetic Dyslipidemia

Vipul Save, MSc

Department of Biochemistry, Lokamanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India; 2, Pragati CHS, Manjrekar Road, Dadar, Mumbai-400028, India; vipulcs{at}gmail.com

Neela Patil, PhD

Department of Biochemistry Lokamanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India

Nivedita Moulik, MD

Girish Rajadhyaksha, MD

Department of Medicine, Lokamanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India

Hyperlipidemia is commonly observed in patients with type 2 diabetes and is an independent risk factor for cardiovascular disease. The authors tested the effect of atorvastatin (10 mg/d) on 110 hyperlipidemic type 2 diabetes patients with low-density lipoprotein cholesterol (LDL-C) levels exceeding 130 mg/d. The primary efficacy end point was the percentage change in LDL-C and high-density lipoprotein cholesterol (HDL-C), and secondary efficacy included the percentage change in apolipoproteins at weeks 6, 12, and 24. The tertiary goal was percentage change in free radical scavenger enzymes and oxidative stress. LDL-C was reduced by 25%, 39.3%, and 49.2%. A similar trend was observed in total cholesterol, triglyceride, non-HDL-C, and apolipoprotein (apo) B-100. HDL-C was raised by 3.2%, 6%, and 8.2%. A similar trend was seen in apo A-1. Copper zinc-superoxide dismutase and glutathione were raised significantly (P < .001); however, changes in glutathione-S-transferase and glutathione peroxidase activities were nonsignificant. Malondialdehyde was decreased significantly (P < .001). Atorvastatin improves the lipoprotein profile and oxidative status in patients with type 2 diabetes.

Key Words: atorvastatin • type 2 diabetes • hyperlipidemia • LDL-C • apo B-100 • malondialdehyde • antioxidant enzyme

References

  • American diabetes association clinical practice recommendation. Diabetes Care. 1998;21:179-182.[ISI][Medline] [Order article via Infotrieve]
  • Manzato E, Zambon A, Lapolla A, et al. Lipoprotein abnormalities in well treated type II diabetic patients. Diabetes Care. 1993;16:469-475.[Abstract]
  • Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA. 2001;285: 2486-2497.[Free Full Text]
  • Consensus statement detection and management of lipid disorder in diabetes. Diabetes Care. 1993;16:106-112.
  • Gotto AM Jr, Whitney E, Stein EA. Relation between baseline and on-treatment lipid parameter and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-484.
  • Brunzell JD, Hazzard WR, Motuskly AG, et al. Evidence for diabetes mellitus and genetic forms of hypertriglyceridemia as independent entities. Metabolism. 1975;24:1115-1121.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Pyorala K, Pederson TR, Kjekshus J. Cholesterol lowering with simvastatin improves prognosis of diabetes patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.[Abstract]
  • Matsuzki M, Kita T, Mabuchi H, et al. Larger scale cohort study of the relationship between serum cholesterol concentration and coronary events with low dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J. 2002;66:1087-1095.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Alkawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor cerivastatin suppresses growth of macrophages expressing matrix metalloproteinase and tissue factor in vivo and in vitro. Circulation. 2001;103: 276-283.
  • Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.[Abstract/Free Full Text]
  • Riesen WF, Engler H, Rish M, et al. Short term effects of atorvastatin on C-reactive protein. Eur Heart J. 2002;23:794-799.[Abstract/Free Full Text]
  • McCord JM, Fridovich I. Superoxide dismutase on enzymatic function for erythrocuprein. J Biol Chem. 1969;22:6049-6055.
  • Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34:497-500.[Abstract/Free Full Text]
  • Boyne AF, Ellman GL. A methodology for analysis of tissue sulfhydryl components. Anal Biochem. 1972;46:639-653.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Paglia DE, Valentine WN. Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Clin Chem. 1967;70:158-169.
  • William HH, Michael JP, William BJ. Glutathione S-transferase: the first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249:7130-7139.[Abstract/Free Full Text]
  • Sasikala M, Subramanyam C, Sadasivudu B. Early oxidative change in low density lipoproteins during progressive chronic renal failure. Indian J Clin Biochem. 1999;14:176-183.
  • Jones P, Kafonek S, Laurora I. Comparative efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81:582-587.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364: 685-696.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Sever PS, Poulter NR, Dahlof B. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Diabetes Care. 2005;28:1151-1157.[Abstract/Free Full Text]
  • Athyros VG, Papageorgiou AA, Symeonidis AN, et al. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology. 2003;54:679-690.[ISI][Medline] [Order article via Infotrieve]
  • Black DM, Bakker-Arkema R, Heinonen T, et al. Efficacy and safety of atorvastatin in hyperlipidemic patients with concurrent hypertension or non insulin dependent diabetes mellitus. J Hypertens. 1998;16(suppl 2):S233-S233.
  • Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-C by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin a new HMG CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.[Abstract/Free Full Text]
  • Japan Cholesterol Lowering Atorvastatin Study Group. A comparative study of the effect of atorvastatin, a new HMG-CoA reductase inhibitor with pravastatin in primary hyperlipidemia patients. Prog Med. 1998;18:2251-2300.
  • Japan Cholesterol Lowering Atorvastatin Study Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1248-1252.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Atorvastatin Study Group I, Davidson M, McKenney J, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Dart A, Jerms G, Nicholson G, et al. A multicentre, double-bind, one year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39-44.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Davidson MH, Ma PTC, Stein E. ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa and IIb hypercholesterolemia. J Am Coll Cardiol. 2001;37(suppl A):292A-292A. Abstract 1261-175.
  • Schoojans K, Peinado-Onsurbe J, Fruchart JC, et al. 3-hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum TG levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999;452:160-164.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Geneviève M, Hélène D, Christophe B, et al. Statin induced inhibition of the Rho-signaling pathway activates PPAR-alpha and induces HDL apoA-I. J Clin Invest. 2001; 107:1423-1432.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis.1998;141:S57-S62.
  • Grundy SM. Consensus statement role of therapy with "statin" in patients with hypertriglyceridemia. Am J Cardiol. 1998;81:1B-6B.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis. 1990;10:668-671.[Free Full Text]
  • Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990;13:153-169.[Abstract]
  • Mitchell A, Fidge N, Grififths P. The effect of the HMG CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat. Biochem Biophys Acta. 1993;1167:9-14.[Medline] [Order article via Infotrieve]
  • Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. J Clin Pathol. 2004;57:728-734.[Abstract/Free Full Text]
  • Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Harrison DG. Endothelial function and oxidative stress. Clin Cardiol. 1997;20(11 suppl 2):II-11-7-II-11-7.
  • Passi S, Stancato A, Aleo E, et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors. 2003;18:113-124.[ISI][Medline] [Order article via Infotrieve]
  • Yilmaz MI, Baykal Y, Kilic M, et al. Effects of statins on oxidative stress. Biol Trace Elem Res. 2004;98: 119-127.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Sven W, Ulrich L, Kirsten M, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305.[Abstract/Free Full Text]
  • Koichi S, Nobuo F, Katsunori W. Effects of atorvastatin therapy on the low density lipoprotein sub fraction, remnant like particles cholesterol, and oxidized low density lipoprotein within 2 week in hypercholesterolemic patients. Circ J. 2003;67:866-870.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Nishi K, Uno M, Fukuzawa K, et al. Clinicopathological significance of lipid peroxidation in carotid plaques. Atherosclerosis. 2002;160:289-296.[CrossRef][ISI][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Save, V.
Right arrow Articles by Rajadhyaksha, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Save, V.
Right arrow Articles by Rajadhyaksha, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?